Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Nuvectis Pharma, Inc.

NVCT Nasdaq Pharmaceutical Preparations Financials FY2021โ€“FY2025

Last close ยท Oct 23, 2026

$20.05

4.0%
Compare
Revenue Total sales reported in the income statement.
โ€”
vs prior year
Operating margin Operating income as a share of revenue.
โ€”
Net income Profit after all expenses, interest and tax.
โˆ’$26.4M
Free cash flow Cash from operations minus capital spending.
โ€”
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$471M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$1.31 EPS (TTM)

What Nuvectis Pharma, Inc. does

No business description yet.

Legal name
Nuvectis Pharma, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Feb 11, 2026
Accession ยท CIK
0001104659-26-013044
0001875558

Revenue and margins

Nuvectis Pharma, Inc. had โ€” of revenue in fiscal 2025.

Revenue
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โ€” in fiscal 2025, โ€” of revenue. Cash from operations minus capital spending.

Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Nuvectis Pharma, Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 27.5%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Nuvectis Pharma, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $5.7M$20.0M$19.1M$18.5M$31.6M
Current ratio 2.4x3.3x2.7x2.1x2.4x
Quick ratio 2.4x3.3x2.7x2.1x2.4x
Total assets $6.7M$20.4M$19.2M$18.6M$31.7M
Total liabilities $2.4M$6.2M$7.0M$8.9M$13.3M
Shareholders' equity โˆ’$11.0M$14.2M$12.2M$9.7M$18.4M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ“ โœ• โœ“ โœ“
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โœ“ โœ• โœ• โœ“
Share count didn't rise โ€” โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โ€” โ€” โ€” โ€”
F-score โ€” / 3โ€” / 6โ€” / 6โ€” / 6โ€” / 6
Accruals ratio โˆ’50.9%โˆ’40.8%โˆ’31.9%โˆ’35.7%โˆ’41.5%
Altman Z'' โˆ’20.75โˆ’4.46โˆ’11.23โˆ’15.43โˆ’10.83

5 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY21FY22FY23FY24FY25
Income statement
Research and development $9.5M $13.2M $15.4M $12.9M $18.2M
Operating income โˆ’$12.9M โˆ’$19.2M โˆ’$22.9M โˆ’$19.8M โˆ’$27.6M
Net income โˆ’$12.9M โˆ’$19.1M โˆ’$22.3M โˆ’$19.0M โˆ’$26.4M
Net income to common โˆ’$12.9M โˆ’$19.1M โˆ’$22.3M โˆ’$19.0M โˆ’$28.9M
Diluted EPS โˆ’$3.02 โˆ’$1.51 โˆ’$1.43 โˆ’$1.11 โˆ’$1.32
Diluted shares 0.00B 0.01B 0.02B 0.02B 0.02B
Cash flow
Cash from operations โˆ’$9.5M โˆ’$13.6M โˆ’$16.0M โˆ’$12.2M โˆ’$16.0M
Stock-based compensation $1.9M $1.7M $4.7M $4.9M $6.0M
Balance sheet
Cash and short-term investments $5.7M $20.0M $19.1M $18.5M $31.6M
Current assets $5.8M $20.4M $19.2M $18.6M $31.7M
Current liabilities $2.4M $6.2M $7.0M $8.9M $13.3M
Total assets $6.7M $20.4M $19.2M $18.6M $31.7M
Total liabilities $2.4M $6.2M $7.0M $8.9M $13.3M
Shareholders' equity โˆ’$11.0M $14.2M $12.2M $9.7M $18.4M
Returns
Return on capital employed โˆ’304.2% โˆ’135.3% โˆ’187.7% โˆ’204.3% โˆ’149.8%
Return on equity โ€” โˆ’1,188.7% โˆ’168.5% โˆ’173.4% โˆ’188.0%
Return on assets โˆ’193.6% โˆ’141.0% โˆ’112.5% โˆ’100.6% โˆ’105.1%
Return on tangible equity โ€” โˆ’134.2% โˆ’182.4% โˆ’195.6% โˆ’156.8%
Growth
Share count change โ€” 196.6% 22.9% 10.0% 27.5%
Financial health
Current ratio 2.4x 3.3x 2.7x 2.1x 2.4x
Quick ratio 2.4x 3.3x 2.7x 2.1x 2.4x
Quality scores
Altman Z'' โˆ’20.7 โˆ’4.5 โˆ’11.2 โˆ’15.4 โˆ’10.8
Accruals ratio โˆ’50.9% โˆ’40.8% โˆ’31.9% โˆ’35.7% โˆ’41.5%

Source: SEC EDGAR XBRL filings (CIK 0001875558). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open